Bixlenvo offers a simplified option for patients whose HIV is under control but who can’t use current single-pill treatments.

The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to ...

As the first second-generation INSTI approved for newborns with HIV, this approval allows for a simpler, more robust antiretroviral therapy regimen than existing standard of care.

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD ...

Globally, around 2.6 million children and adolescents are currently living with HIV, the majority of them in Africa. These young people are much more likely to experience treatment failure than adults ...

HIV doesn’t discriminate, but societal barriers have left Black Americans disproportionately affected. HIV prevention options could help.

For years, Nigeria’s fight against HIV has centred on testing, treatment and condom use. However, a new chapter is emerging in the country’s prevention ...

An infectious disease specialist discusses HIV prevention barriers facing Black women and how long-acting options and ...

Second Study in ACTG’s Small Clinical Trials Advancing HIV Remission and Cure ProgramCHAPEL HILL, N.C., Aug. 19, 2026 (GLOBE ...

Uninterrupted access to HIV treatment suppresses the virus to undetectable levels, protecting the immune system and stopping ...

For National Faith HIV & AIDS Awareness Day, NMAC’s Jennifer Moore Phillips argues that trusted, accountable faith ...